Trending Stock News

King Luther Capital Management Increased By $2.65 Million Its Ceco Environmental (CECE) Position; Enanta Pharmaceuticals, Inc. (ENTA) Covered By 1 Bullish Analysts Last Week

Among 6 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Enanta Pharmaceuticals Inc had 24 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by J.P. Morgan to “Hold” on Thursday, February 8. JMP Securities downgraded the stock to “Market Perform” rating in Thursday, April 28 report. JP Morgan downgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Thursday, February 8 to “Neutral” rating. RBC Capital Markets downgraded the shares of ENTA in report on Tuesday, January 2 to “Sector Perform” rating. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, April 4. RBC Capital Markets maintained the shares of ENTA in report on Monday, November 20 with “Buy” rating. The company was maintained on Friday, September 15 by Robert W. Baird. The firm has “Neutral” rating by Robert W. Baird given on Tuesday, August 8. Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Thursday, February 8 with “Hold” rating. On Friday, October 20 the stock rating was maintained by Robert W. Baird with “Hold”. See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) latest ratings:

04/04/2018 Broker: RBC Capital Markets Rating: Hold New Target: $80.0000 Maintain
08/02/2018 Broker: J.P. Morgan Rating: Hold Downgrade
08/02/2018 Broker: Robert W. Baird Rating: Hold New Target: $82.0 Maintain
08/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade
02/01/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Old Target: $54 Downgrade
20/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $46.0 Maintain
20/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $58.0 Maintain

King Luther Capital Management Corp increased Ceco Environmental Corp (CECE) stake by 29.88% reported in 2017Q4 SEC filing. King Luther Capital Management Corp acquired 530,180 shares as Ceco Environmental Corp (CECE)’s stock declined 11.39%. The King Luther Capital Management Corp holds 2.30 million shares with $11.82 million value, up from 1.77 million last quarter. Ceco Environmental Corp now has $228.92M valuation. The stock increased 5.61% or $0.35 during the last trading session, reaching $6.59. About 224,640 shares traded or 35.60% up from the average. CECO Environmental Corp. (NASDAQ:CECE) has declined 56.72% since May 17, 2017 and is downtrending. It has underperformed by 68.27% the S&P500.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: which released: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2018 Results – Earnings Call Transcript” on May 09, 2018, also with their article: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” published on May 08, 2018, published: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: and their article: “Benzinga’s Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss” published on May 03, 2018 as well as‘s news article titled: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” with publication date: May 04, 2018.

Since March 19, 2018, it had 0 insider purchases, and 2 selling transactions for $1.14 million activity. Adda Nathalie had sold 4,225 shares worth $361,560. 9,000 shares were sold by MELLETT PAUL J, worth $778,331 on Monday, March 19.

The stock increased 0.70% or $0.74 during the last trading session, reaching $106.12. About 143,848 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since May 17, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.

Investors sentiment decreased to 1.58 in Q4 2017. Its down 0.02, from 1.6 in 2017Q3. It fall, as 12 investors sold Enanta Pharmaceuticals, Inc. shares while 36 reduced holdings. 29 funds opened positions while 47 raised stakes. 13.64 million shares or 12.66% more from 12.10 million shares in 2017Q3 were reported. Td Asset reported 13,134 shares. Pub Sector Pension Investment Board holds 0% or 8,835 shares in its portfolio. Clarivest Asset Management Ltd Limited Liability Company invested in 0.02% or 15,200 shares. Metropolitan Life Insurance invested in 0% or 5,002 shares. State Common Retirement Fund holds 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) or 39,238 shares. Vanguard Gp invested in 821,687 shares. Virginia Retirement Et Al has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 21,100 shares. Jacobs Levy Equity Management reported 29,400 shares. Schwab Charles Investment Mngmt accumulated 97,272 shares. 771,600 are held by Renaissance Tech Ltd. Gsa Cap Prtn Limited Liability Partnership, United Kingdom-based fund reported 9,400 shares. State Teachers Retirement Sys owns 38,490 shares for 0.01% of their portfolio. Invesco Ltd invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Qs Invsts Llc has invested 0.04% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Thrivent Financial For Lutherans holds 8,906 shares.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $2.05 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 60.61 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

King Luther Capital Management Corp decreased Cvs Corp (NYSE:CVS) stake by 18,055 shares to 140,979 valued at $10.22 million in 2017Q4. It also reduced Fmc Corp (NYSE:FMC) stake by 186,359 shares and now owns 2.61M shares. Colgate Palmolive Co (NYSE:CL) was reduced too.

More important recent CECO Environmental Corp. (NASDAQ:CECE) news were published by: which released: “Consolidated Research: 2018 Summary Expectations for Care, Unilever, CECO Environmental, Carter’s, ObsEva SA …” on May 14, 2018, also published article titled: “CECO Environmental’s (CECE) CEO Dennis Sadlowski on Q1 2018 Results – Earnings Call Transcript”, published: “Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting” on May 08, 2018. More interesting news about CECO Environmental Corp. (NASDAQ:CECE) was released by: and their article: “55 Biggest Movers From Yesterday” with publication date: May 11, 2018.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.03, from 0.88 in 2017Q3. It increased, as 20 investors sold CECE shares while 34 reduced holdings. 21 funds opened positions while 28 raised stakes. 22.39 million shares or 1.39% less from 22.71 million shares in 2017Q3 were reported. Ameriprise Fincl reported 11,037 shares. California State Teachers Retirement Sys holds 47,441 shares. Bankshares Of Montreal Can holds 0% or 431 shares in its portfolio. Finemark Savings Bank & Tru reported 11,957 shares. American Century accumulated 1.23M shares or 0.01% of the stock. Federated Pa has invested 0% in CECO Environmental Corp. (NASDAQ:CECE). State Board Of Administration Of Florida Retirement Sys stated it has 17,063 shares or 0% of all its holdings. Millennium Ltd Limited Liability Company reported 41,320 shares. 13,483 were reported by Macquarie Ltd. 27,142 are held by Connors Investor Svcs. Guyasuta Invest reported 0.06% stake. Minerva Advisors Ltd Liability Corporation holds 150,922 shares or 0.41% of its portfolio. Bnp Paribas Arbitrage has 0% invested in CECO Environmental Corp. (NASDAQ:CECE) for 8,642 shares. Janney Montgomery Scott Ltd Liability holds 0% or 31,556 shares. Teton Inc holds 17,720 shares or 0.01% of its portfolio.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *